WithdrawnPhase 4

Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation

Lead sponsor

Cedars-Sinai Medical Center

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

Primary endpoints

•Liver glucokinase activity (acute effect)•Liver glucokinase activity (chronic effect)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02198209

Org study IDU1111-1138-7223

Timeline

Milestones

Study first posted2014-07-23estimated

Last update posted2019-09-30actual

Study start2019-12estimated (month precision)

Primary completion2020-07estimated (month precision)

Study completion2020-12estimated (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•18- 65 years of age (inclusive)

•Ability to provide informed consent before any trial-related activities

•Ability to communicate effectively with research staff

•Ability to return for follow up visit

•Adequate IV access

•If a female of childbearing potential, non-pregnant and taking reliable contraception

•Documented T2DM (per most recent American Diabetes Association criteria);

•Drug naïve or treated with metformin only;

•Diabetes should be well controlled (as defined by HbA1 ≤ 7.5%, FPG <180 mg/dl).

Exclusion criteria

•Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures

•Presence of cancer or any clinically significant cardiac, respiratory, renal, hepatic, gastrointestinal, endocrinological, haematological, neurological, or psychiatric diseases or disorders (inclusion will be discussed with attending physician)

•Liver disease; history of alcoholism.

•Known or suspected allergy to liraglutide

•Contraindications to liraglutide: patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2

•Patients with a history of pancreatitits

•Patients that have been treated with drugs that promote weight loss (e.g., Xenical® [orlistat], Meridia® [sibutramine], Acomplia® [rimonabant], Acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of study start

•Patients that have been treated with diabetes drugs: injectables, (e.g GLP-1R agonists (Byetta® [exenatide], Victoza® [liraglutide]) amylin analogues; insulin and insulin analogues) or oral agents other than metformin (e.g.DPP-IV- inhibitors (Januvia® [sitagliptin], Onglyza® [saxagliptin] or Janumet® [sitagliptin and metformin]),insulin sensitizers (thiazolidindiones: pioglitazone [Actos®]); or sulfonylureas) within 3 months of study start.

•The receipt of any investigational drug within 3 months prior to study start.

•Type 1 diabetes

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Other (unclassified)

Glycemic / diabetes

3 endpoints

Primary/protocol endpoint/low confidence

Liver glucokinase activity (chronic effect)

Time frame:12 months

change from baseline, improvement

Secondary/protocol endpoint

insulin sensitivity

Time frame:12 months

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Acute insulin response to glucose and the disposition index

Time frame:12 months

change from baseline, improvement

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Liver glucokinase activity (acute effect)

Time frame:12 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.